Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Кафедра психиатрии, психотерапии и психосоматической патологии ФПК МР Медицинского института ФГБОУ ВПО РУДН. 117198, Россия, Москва, ул. Миклухо-Маклая, д. 8, корп. 1
Список исп. литературыСкрыть список 1. Волошин В.М., Шилова А.М. Феварин при терапии обсессивно-компульсивных расстройств в детско-подростковой психиатрической практике. Фарматека. 2006; 7: 109–13. / Voloshin V.M., Shilova A.M. Fevarin pri terapii obsessivno-kompul'sivnykh rasstroistv v detsko-podrostkovoi psikhiatricheskoi praktike. Farmateka. 2006; 7: 109–13. [in Russian] 2. Дороженок И.Ю., Терентьева М.А. Феварин в дерматологической клинике (терапия депрессий и обсессивно-компульсивных расстройств). Психиатр. и психофармакотер. 2006; 1: 24–6. / Dorozhenok I.Iu., Terent'eva M.A. Fevarin v dermatologicheskoi klinike (terapiia depressii i obsessivno-kompul'sivnykh rasstroistv). Psikhiatr. i psikhofarmakoter. 2006; 1: 24–6. [in Russian] 3. Колюцкая Е.В. Флувоксамин (Феварин) в терапии обсессивно-компульсивных расстройств. Фарматека. 2006; 2: 30–9. / Koliutskaia E.V. Fluvoksamin (Fevarin) v terapii obsessivno-kompul'sivnykh rasstroistv. Farmateka. 2006; 2: 30–9. [in Russian] 4. Медведев В.Э. Психические расстройства у пациентов пластического хирурга. Вопр. челюстно-лицевой, пластич. хирургии, имплантологии и клин. стоматологии. 2010; 5–6: 11–8. / Medvedev V.E. Psikhicheskie rasstroistva u patsientov plasticheskogo khirurga. Vopr. cheliustno-litsevoi, plastich. khirurgii, implantologii i klin. stomatologii. 2010; 5–6: 11–8. [in Russian] 5. Медведев В.Э., Барсегян Т.В., Дробышев А.В. Терапия депрессивных и тревожных расстройств у пациентов, обращающихся за хирургической коррекцией внешности. Психич. здоровье. 2012; 5 (72): 40–5. / Medvedev V.E., Barsegian T.V., Drobyshev A.V. Terapiia depressivnykh i trevozhnykh rasstroistv u patsientov, obrashchaiushchikhsia za khirurgicheskoi korrektsiei vneshnosti. Psikhich. zdorov'e. 2012; 5 (72): 40–5. [in Russian] 6. Стась С.Ю. Обсессии контрастного содержания (аспекты коморбидности с расстройствами бредового регистра). Психиатрия (научно-практич. журн.). 2007; 2: 7–15. / Stas' S.Iu. Obsessii kontrastnogo soderzhaniia (aspekty komorbidnosti s rasstroistvami bredovogo registra). Psikhiatriia (nauchno-praktich. zhurn.). 2007; 2: 7–15. [in Russian] 7. Anderson RC. Body dysmorphic disorder: recognition and treatment. Plast Surg Nurs 2003 Fall; 23 (3): 125–8. 8. Arnold L. Psychiatric Times 1999; XVI: 65–9. 9. Bienvenu OJ, Samuels JF, Riddle MA et al. The relationship of obsessive-compulsive disorder to possible spectrum disorders: results from a family study. Biol Psychiatry 2000; 48 (4): 287–93. 10. Biraben-Gotzamanis L, Aouizerate B, Martin-Guehl C et al. Body dysmorphic disorder and cosmetic surgery: assessment of 24 subjects with a minimal defect in appearance 5 years after their request for cosmetic surgery. Presse Med 2009; 38 (7–8): 1062–7. 11. Cherian АV, Math SB, Kandave Th, Reddy JYC. A 5-year prospective follow-up study of patients with obsessive-compulsive disorder treated with serotonin reuptake inhibitors. J Affect Disord 2014; 152–154: 387–94. 12. Crino R, Slade T, Andrews G. The changing prevalence and severity of obsessive-compulsive disorder criteria from DSM-III to DSM-IV. Am J Psychiatry 2005; 162: 876–82. 13. De Ruiter C, Rijken H, Garssen B et al. Comorbidity among the anxiety disorders. J Anx Dis 1989; 3: 57–68. 14. Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. European Neuropsychopharmacol 2005; 15: 69–74. 15. Fineberg N. Evidence-Based Pharmacotherapy for Obsessive-Compulsive Disorder. Advances Psychiatr Treatment; 1999: 5 (5): 357–65. 16. Frarea F, Perugi G, Ruffolob G, Tonic C. Obsessive–compulsive disorder and body dysmorphic disorder: a comparison of clinical features. Eur Psychiatry 2004; 19 (5): 292–8. 17. Fulton B, McTavish D. Fluoxetine. CNS Drugs 1995; 3: 305–22. 18. Gupta PR. Emergence of kleptomania during treatment for obsessive compulsive disorder with fluvoxamine. Indian J Psychiatry 2014; 56 (1): 100–1. 19. Heidari M, Zarei M, Hosseini SM et al. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. Int Clin Psychopharmacol 2014; 29 (6): 344–50. 20. Hollander E. Obsessive-compulsive disorder and spectrum across the life span. Int J Psychiatry Clin Practice 2005; 9 (2): 79–86. 21. Jefferson J. Algorithm for the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 1995; 31: 487–90. 22. Jenike MA, Rauch SL. Managing the patient with treatment resistant obsessive compulsive disorder: Current strategies. J Clin Psychiatry 1994; 55: 11–7. 23. Karno M, Golding JM. Psychiatric disorder in America: The epidemiologic Catchment Area Study. Free press NY 1991. 24. Katzman MA, Bleau P, Blier P et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014; 14 (Suppl. 1): S1. 25. Kindler S, Dannon PN, Iancu I et al. Emergence of kleptomania during treatment for depression with serotonin selective reuptake inhibitors. Clin Neuropharmacol 1997; 20: 26–9. 26. Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol 1997; 17 (4): 267–71. 27. Pavan C, Simonato P, Marini M et al. Psychopathologic aspects of body dysmorphic disorder: a literature review. Aesthetic Plast Surg 2008; 32 (3): 473–84. 28. Phillips KA. Body dysmorphic disorder: clinical aspects and treatment strategies. Bull Menninger Clin 1998 Fall; 62 (4 Suppl. A): 33–48. 29. Phillips KA, Coles ME, Menard W et al. Suicidal ideation and suicide attempts in body dysmorphic disorder. J Clin Psychiatry 2005; 66 (6): 717–25. 30. Tollefson GD, Rampey AH Jr, Potzin JH et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive. Arch Gen Psychiatry 1994; 51: 559–67. 31. Van Balkom AJ, Emmelkamp PM, Eikelenboom M et al. Cognitive therapy versus fluvoxamine as a second-step treatment in obsessive-compulsive disorder nonresponsive to first-step behavior therapy. Psychother Psychosom 2012; 81 (6): 366–74. 32. Westenberg HМ, Sandoz C. Tolerability and safety of fluvoxamine and other antidepressants. J Clin Pract 2006; 4: 482–91.